Posted Final JA Redact.pdf

This document is a redacted justification and approval for a sole source contract awarded by the Department of Health and Human Services Assistant Secretary for Preparedness and Response. The contract is for research and development of monoclonal antibody mAb114 to treat Ebola and was awarded non-competitively to Ridgeback Biotherapeutics LP as the only responsible source able to meet the agency's requirements. The justification cites Federal Acquisition Regulation 6.302-1 as the authority for this sole source award due to Ridgeback Biotherapeutics' unique qualifications to perform the work based on its experience and capabilities developing mAb114, which has demonstrated protective effects in multiple animal models and has advanced to clinical testing in humans.